期刊文献+

HIV-1C亚型nef基因构建的DNA质粒诱导小鼠免疫反应的研究 被引量:1

Cellular and humoral immune responses induced by DNA plasmid constructed by HIV-1 clade C nef gene
原文传递
导出
摘要 目的构建表达中国流行株HIV-1C亚型调控nef基因的重组质粒pVAX-nef,并免疫BALB/c小鼠,观察其免疫效果,为探索新型HIV DNA疫苗提供数据。方法利用分子生物学技术,将nef基因克隆到pVAX,并在体外进行表达与鉴定。以纯化的Nef蛋白作为包被抗原,用ELISA检测其体液免疫反应,用ELISPOT检测其细胞免疫反应。结果重组质粒pVAX-nef成功构建。接种小鼠后2周,ELISPOT结果显示产生了针对HIV特异的CD4和CD8细胞抗原表位的免疫应答,且与免疫剂量存在一定的正相关性。ELISA实验诱导产生了抗HIV-1特异性抗体,其中40μg免疫组诱导的抗体水平最高。结论重组质粒pVAX-nef免疫小鼠后可有效地诱导机体产生细胞免疫和体液免疫反应。 Objective To construct DNA plasmid expressing HIV-1 clade C nef gene and to investigate its cellular and humoral immune responses. Methods The HIV-1 clade C nef gene was inserted into expression vector pVAX to construct the recombinant plasmid, pVAX-nef. The recombinant plasmid was transfected into 293T cell. Western blot was performed to examine the expression of nef gene. BALB/c mice were immunized with the recombinant plasmid and then the cellular immune response was analyzed by ELISPOT assay, the humoral immune response was tested by ELISA method. Results The pVAX-nef recombinant placid was successfully constructed and the Nef protein was successfully expressed in 293T cell. Two weeks after pVAX-nef recombinant plasmid inoculation, HIV-specific CD4^+ and CD8^+ immune responses were detected by ELISPOT assay, with a positive correlation between the dose of the recombinant plasmid and the immune response. ELISA method showed that anti-HIV-1 was successfully induced and the mice immunized with 40 μg pVAX-nef recombinant plasmid produced a highest level of anti-HIV-1. Conclusion The HIV-1 clade C DNA plasmid pVAX-nef could effectively induce cellular and humoral immune responses in BALB/c mice. These immunological effects showed positive correlation with immunization dose.
出处 《中华微生物学和免疫学杂志》 CAS CSCD 北大核心 2006年第9期777-780,共4页 Chinese Journal of Microbiology and Immunology
基金 国家863基金项目(2005AA218030)
关键词 HIV-1C亚型 DNA疫苗 免疫反应 HIV-1 clade C DNA plasmid Immunoreaction
  • 相关文献

参考文献9

  • 1Mwau M,McMichael AJ.A review of vaccines for HIV prevention.J Gene Med,2003,5(1):3-10.
  • 2Alexandra B,Ludwig D,Ralf W.The past,present and future of HIV-vaccine development:a critical view.Therapeutic Focus,2002,7:36-46.
  • 3Das SR,Jameel S.Biology of the HIV Nef protein.Indian J Med Res,2005,121(4):315-332.
  • 4Kaufnan J,Jing J.China and AIDS-the time to act is now.Science,2002,296:2339-2340.
  • 5李大勤,郑锡文,张桂云,田春桥,曲书泉.中国云南省瑞丽等地艾滋病病毒I型C亚型的分布研究[J].中华流行病学杂志,1996,17(6):337-339. 被引量:5
  • 6J萨姆布鲁克 DW拉塞尔.分子克隆实验指南.第三版[M].北京:科学出版社,2002..
  • 7Letvin NL.Progress in the development of an HIV-1 vaccine.Science,1998,280:1875-1880.
  • 8Nabel GJ.Challenges and opportunities for development of an AIDS vaccine.Nature,2001,410:1002-1007.
  • 9Joseph AM,Kumar M,Mitra D.Nef:"necessary and enforcing factor"in HIV infection.Curr HIV Res,2005,3(1):87-94.

二级参考文献3

  • 1Luo C,The Lancet,1995年,345卷,1051页
  • 2郑锡文,中华流行病学杂志,1994年,15卷,3页
  • 3匿名著者,1994年

共引文献5

同被引文献14

  • 1Maltez F, Doroana M, Branco T, et al. Recent advances in antiretroviral treatment and prevention in HIV-infected patients [J]. Curr Opin HIV AIDS, 2011,6(Snppl 1):21 -30.
  • 2Grant M, Samuel R, Bettiker R L, et al. Antiretroviral therapy 2010 update: current practices and controversies [J]. Arch Pharm Res, 2011,34(7) :1045- 1053.
  • 3Butler S L, Valdez H, Westby M, et al. Disease-modifying therapeutic concepts for HIV in the era of highly active antiretroviral therapy [J]. J Acquir Immune Defic Syndr, 2011,58(3) :297 -303.
  • 4Walker A S, Gibb D M. Monitoring of highly active antiretroviral therapy in HIV infection [ J ]. Curr Opin Infect Dis, 2011,24( 1 ) :27 - 33.
  • 5Boyd M A. Improvements in antiretroviral therapy outcomes over calendar time [ J ]. Curr Opin HIV AIDS, 2009,4 ( 3 ) : 194 - 199.
  • 6Reynell L, Trkola A. HIV vaccines: an attainable goal? [J]. Swiss Med Wkly, 2012,142:w13535.
  • 7Barouch D H, Korber B. HIV-1 vaccine development after STEP[J]. Annu Rev Med,2010,61 : 153 - 167.
  • 8Zhang H, Hong H, Li D, et al. Comparing pooled peptides with intact protein for accessing cross-presentation pathways for protective CD8^+ and CD4^+ T cells [ J ]. J Biol Chem, 2009,284(14) :9184 -9191.
  • 9Rodriguez A M, Pascutti M F, Maeto C, et al. IL-12 and GM-CSF in DNA/MVA immunizations against HIV-1 CRF12_BF Nef induced T-Cell responses with an enhanced magnitude, breadth and quality [ J ]. PLoS One 2012,7 (5) :e37801.
  • 10Genesca M. Characterization of an effective CTL response against HIV and SIV infections [ J ]. J Biomed Biotechnol, 2011,2011 : 103924.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部